文献速递淋巴瘤白血病

Epcoritamab单药治疗Richter转化(EPCORE CLL-1):单臂、多中心、开放标签1b/2期试验结果

Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial.
PubMed 文献 · Lancet Haematol · 2025-12-08

这项在9个国家24个中心开展的单臂、开放标签1b/2期试验评估了皮下CD3×CD20双特异性抗体epcoritamab单药治疗Richter转化的安全性和初步活性。42例患者中,研究者评估的总缓解率为47.6%(95%CI 32.0-63.6),未达到预设的50%替代假设。最常见3-4级不良事件为中性粒细胞减少(45%)、贫血(38%)和血小板减少(38%)。

要点

  • 42例Richter转化患者接受epcoritamab单药治疗,总缓解率47.6%(95%CI 32.0-63.6)。
  • 一线Richter转化人群总缓解率57.1%,二线及以上人群38.1%。
  • 细胞因子释放综合征发生率86%,其中3级占7%。

核心结论

  • 在Richter转化患者中,epcoritamab单药显示出有临床意义的抗肿瘤活性,但研究者评估的总缓解率低于50%的替代假设,安全性特征与既往研究一致。
  • 这些发现支持进一步研究epcoritamab作为Richter转化患者的潜在治疗选择。

研究设计与样本

  • 这是一项在多中心、开放标签的1b/2期试验,在9个国家(澳大利亚、比利时、丹麦、德国、以色列、意大利、西班牙、荷兰和美国)的24个中心开展。
  • 入组患者年龄≥18岁,经组织学确诊为Richter转化(弥漫大B细胞淋巴瘤[DLBCL]),美国东部肿瘤协作组体能状态评分为0-2,且既往接受过至多2线针对Richter转化的治疗。
  • 本报告描述扩展组2A(epcoritamab单药)的结果;扩展组还包括epcoritamab联合来那度胺(2B组)和epcoritamab联合利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松(R-CHOP;2C组)。
  • epcoritamab皮下给药,采用阶梯递增剂量后,第1-3周期每周48 mg,第4-9周期每2周一次,此后每4周一次,直至疾病进展或不可接受的毒性。
  • 主要终点为研究者根据Lugano 2014标准评估的总体缓解率,在全分析集(所有接受≥1剂epcoritamab的患者)中评估,检验30%的无效假设对50%的替代假设。

主要发现

  • 2021年10月18日至2025年3月21日期间入组42例Richter转化患者;中位年龄69岁(范围50-80),男性32例(76%),女性10例(24%)。
  • 从慢性淋巴细胞白血病或小淋巴细胞淋巴瘤诊断至Richter转化的中位时间为7.6年(范围0-23.9);21例(50%)患者将epcoritamab作为一线Richter转化治疗。
  • 中位随访22.9个月(范围0.5-39.9)时,42例中20例缓解,研究者评估的总缓解率为47.6%(95%CI 32.0-63.6),未达到预设的50%替代假设。
  • 一线人群总缓解率为57.1%(95%CI 34.0-78.2;21例中12例缓解),二线及以上人群为38.1%(95%CI 18.1-61.6;21例中8例缓解),基线有TP53异常和/或del(17p)的20例患者中8例缓解(40%,95%CI 19.1-63.9)。
  • 最常见的3-4级不良事件为中性粒细胞减少19例(45%)、贫血16例(38%)、血小板减少16例(38%)、感染9例(21%)、肺炎4例(10%)和COVID-19 2例(5%);细胞因子释放综合征36例(86%),其中3级3例(7%);免疫效应细胞相关神经毒性综合征5例(12%;均为1-2级);临床肿瘤溶解综合征2例(5%;均为1-2级)。

关键数值与推荐

  • 主要终点总缓解率在全分析集中评估,检验30%的无效假设对50%的替代假设。
  • 总体缓解率47.6%(95%CI 32.0-63.6)未达到预设的50%替代假设。
  • 预设亚组分析按Richter转化治疗线数和TP53异常和/或del(17p)状态进行。

临床怎么用

  • 原文结论指出epcoritamab单药在Richter转化患者中显示出有临床意义的抗肿瘤活性,但总缓解率低于50%的替代假设。
  • 原文结论支持进一步研究epcoritamab作为Richter转化患者的潜在治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Richter transformation is one of the most challenging B-cell lymphomas to treat, particularly in patients with high-risk chronic lymphocytic leukaemia features or who have had previous therapy for chronic lymphocytic leukaemia. Median survival remains 6-12 months across various therapeutic approaches. We evaluated the safety and preliminary activity of epcoritamab monotherapy, a subcutaneous CD3×CD20 bispecific antibody, in patients with Richter transformation. METHODS: This multicentre, open-label, phase 1b/2 trial was conducted at 24 centres in nine countries (Australia, Belgium, Denmark, Germany, Israel, Italy, Spain, The Netherlands, and USA). Eligible patients were aged 18 years or older and had histologically confirmed Richter transformation (diffuse large B-cell lymphoma [DLBCL]), an Eastern Cooperative Oncology Group performance status of 0-2, and up to two previous lines of Richter transformation-directed therapy. The trial includes dose-escalation and dose-expansion phases. The expansion groups evaluate epcoritamab monotherapy (group 2A), epcoritamab plus lenalidomide (group 2B), and epcoritamab plus the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; group 2C). The current report describes results from group 2A. Epcoritamab was administered subcutaneously in step-up doses followed by 48 mg every week for cycles 1-3, every 2 weeks for cycles 4-9, and every 4 weeks thereafter until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed overall response rate per Lugano 2014 criteria in the full analysis set (all patients who received ≥1 dose of epcoritamab). It was evaluated against a null hypothesis of 30% versus an alternative of 50%. Prespecified subgroup analyses by line of therapy for Richter transformation and TP53 aberration and/or del(17p) status were performed. Safety was assessed in all treated patients. This trial is ongoing and registered with ClinicalTrials.gov, NCT04623541. FINDINGS: Between Oct 18, 2021, and March 21, 2025, we enrolled 42 patients with Richter transformation. The median age was 69 years (range 50-80); and 32 (76%) of 42 patients were male and ten (24%) were female. Race or ethnicity data were available for 40 patients (37 [88%] identified as White, two [5%] as Asian, and one [2%] as Black or African American; ethnicity was not reported for two patients). The median time from diagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma to Richter transformation was 7·6 years (range 0-23·9). 21 (50%) of 42 patients received epcoritamab as first-line Richter transformation-directed therapy. At a median follow-up of 22·9 months (range 0·5-39·9), 20 of 42 patients had a response with an investigator-assessed overall response rate of 47·6% (95% CI 32·0-63·6), which did not meet the prespecified alternative hypothesis (50%). Overall response occurred in 12 of 21 patients in the first-line population (overall response rate 57·1%, 34·0-78·2), in eight of 21 patients in the second-line or later-line population (38·1%, 18·1-61·6), and in eight of 20 patients with TP53 aberration and/or del(17p) alteration at baseline (40%, 19·1-63·9). The most common grade 3-4 adverse events were neutropenia in 19 (45%) of 42 patients, anaemia in 16 (38%) patients, thrombocytopenia in 16 (38%) patients, infection in nine (21%) patients, pneumonia in four (10%) patients, and COVID-19 in two (5%) patients. Cytokine release syndrome occurred in 36 (86%) patients with three (7%) being grade 3, immune effector cell-associated neurotoxicity syndrome in five (12%; all grade 1-2) patients and clinical tumour lysis syndrome in two (5%; all grade 1-2) patients. Three fatal adverse events were reported, one each due to general physical health deterioration in the context of progressive disease, sepsis, and cerebrovascular accident; none were considered by the investigator to be related to study treatment. INTERPRETATION: In patients with Richter transformation, epcoritamab monotherapy showed clinically meaningful antitumour activity, although the investigator-assessed overall response rate was below the alternative hypothesis of 50%, with a safety profile consistent with previous studies. These findings support further investigation of epcoritamab as a potential treatment option for patients with Richter transformation. FUNDING: Genmab A/S and AbbVie.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kater AP, Janssens A, Eradat H, et al. Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial. Lancet Haematol. 2025. PMID: 41380698. doi:10.1016/S2352-3026(25)00327-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。